Bio4t2 announces trial evaluating repeat infusions of CAR-T targeting solid tumors without lymphodepletion
- Written by PR Newswire
![]() |
SAN DIEGO and SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Bio4t2® received regulatory approvals to repeatedly administer patients with T cells engineered to express a chimeric antigen receptor (CAR) targeting BT-001, an antigen on solid tumors identified using the PrismCore™ platform. The CAR-T, termed B4t2-001, are predicted to engraft...















